# Table of Contents

## Highlights of This Issue 491

## SPECIAL FEATURES

### CCR 20th Anniversary Commentary

493  
**CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma**  
Susan J. Knox and Ronald Levy

## CCR Translations

495  
**Novel Targets in Head and Neck Cancer: Should We Be Optimistic?**  
Gabriel S. Knigsfeld and Christine H. Chung  
See related article, p. 632

## Molecular Pathways

498  
**Molecular Pathways: Autophagy in Cancer—A Matter of Timing and Context**  
Michelle Cicchini, Vassiliki Karantza, and Bing Xia

505  
**Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells**  
Verline Justilien and Alan P. Fields

## Special Report

514  
**Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology**  

## Review

526  
**HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma**  
Netanya I. Pollock and Jennifer R. Grandis

## CANCER THERAPY: CLINICAL

534  
**Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans**  

544  
**Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck**  
Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woog Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon-Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyeon Lee, Jae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soomyung Paik, and Byoung Chul Cho

553  
**First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma**  

## PERSONALIZED MEDICINE AND IMAGING

561  
**The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma**  
569 High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tah, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudikin, Jose Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquim Arribas, Javier Cortes, Evandro de Azambuja, Martine Picart, and Jose Baselga

577 Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer

585 A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma

594 Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models
Povilas Sladkevicius and Lil Valentin

602 Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer
Justin Botisford-Miller, Hyun-Jin Choi, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Monika Haemmerle, Alpa M. Nick, Sunila Pradeep, Behrouz Zand, Rebecca A. Previs, Chad V. Pecot, Erin King Crane, Wei Hu, Susan K. Lutgendorf, Vahid Afshar-Kharghan, and Anil K. Sood

CANCER THERAPY: PRECLINICAL
611 Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
Jessica Ann Chacon, Amol A. Samai, Jie Qing Chen, Caitlin Ceesay, Charuta Kale, John Robinson, Jeffrey Weber, Patrick Hwu, Shari Pilon-Thomas, and Laszlo Radvanyi

BIOLOGY OF HUMAN TUMORS
622 Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection

632 Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

See related commentary, p. 495

642 Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
Tatsuya Yoshida, Genichiro Ishii, Koichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Shinsuke Iida, Akio Niimi, Kanji Nagai, Yuichiro Ohe, and Atsushi Ochiai
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer


DNA Repair Mutations and Outcomes in Ovarian Cancer—Letter
Robert A. Soslow

DNA Repair Mutations and Outcomes in Ovarian Cancer—Response
Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, and Rochelle L. Garcia

Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Correction: HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer

Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

The cover shows NFκB translocation in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Immunocytochemistry staining shows NFκB (p65) translocation (red is nucleus; green is NFκB; and yellow is overlay [translocation]) in the nucleus of tumor-infiltrating lymphocytes expanded with IL-2 and an anti-4-1BB antibody. For details, see the article by Chacon and colleagues on page 611 of this issue.